The Institute for Clinical and Economic Review (ICER) on Thursday released an Evidence Report assessing the comparative clinical effectiveness and value of tisagenlecleucel (Kymriah, Novartis) and axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead).
The report found that both therapies provided improvements in response rates and survival for patients who have exhausted most other treatment options, and that the drugs are priced in alignment with their clinical value.
Both tisangenlecleucel and axicabtagene ciloleucel were evaluated for use in adults with relapsed or refractory B-cell lymphoma. Axicabtagene ciloleucel received approval for this indication in late 2017, while tisagenlecleucel is currently under FDA evaluation. Tisangenlecleucel was also evaluated for pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), for which it received FDA approval in August 2017.
This Evidence Report will be the subject of an upcoming public meeting of the California Technology Assessment Forum (CTAF) on March 2 in Oakland, California. CTAF is one of ICER’s three independent evidence appraisal committees comprising medical evidence experts, practicing clinicians, methodologists, and leaders in patient engagement and advocacy.
The full Evidence Report can be read here.